Grant of Share Options & PDMR Dealings

Genincode

07/05/2026 07:00

RNS Number : 3194D

GENinCode PLC

07 May 2026

 

 

 

7 May 2026

 

 

GENinCode Plc

("GENinCode" or the "Company")

 

Grant of Share Options, Surrender of Existing Options & PDMR Dealings

 

 

GENinCode Plc (AIM: GENI), the polygenics company focused on the prevention of cardiovascular disease and ovarian cancer, announces that the Company has approved the grant of options over an aggregate of 83,847,292 new ordinary shares of 1 pence each in the Company ('Ordinary Shares') under the 2021 Share Option Plan ('2021 Share Option Plan') to certain directors and employees of the Company (the "New Options"), representing 11.13 per cent. of the Company's existing issued share capital.

 

Background to the New Options grants

 

The Company adopted the 2021 Share Option Plan to enable it to retain and incentivise staff and to reward them for the achievement of its longer-term objectives. The New Options replace 29,856,434 current options ("Existing Options") held by existing option holders, which will be surrendered, and are new grants to those employees who have more recently joined the Group.

 

Terms of the New Options

 

The New Options have an exercise price of 1 pence per share and are exercisable on the second anniversary of the date of grant. The New Options will vest over a 24 month period and have a 10-year term.

 

Surrender of Existing Options

 

In March 2025, the Company granted options to acquire shares in the capital of the Company to certain employees and directors of the Company pursuant to the 2021 Share Option Plan. These options were granted with an exercise price of 3.7 pence per share.

 

For directors and employees the existing options will be surrendered for no consideration (the "Option Surrender"), details for which are outlined below. The board believe it is appropriate to issue new share options in replacement of the existing ones to reflect the Company's current share price and to properly incentivise its employees, including its management.

 

Details of resultant holdings

 

Following the New Options grant and the Option Surrender, details of options held by Directors, PDMRs and other employees of the Company, are as follows:

 

Director's name
Position
Number of options surrendered
Number of New Options granted at 1 pence
Aggregate number of options post grant
Current total beneficial holding of Ordinary Shares
Current holding as a % of Issued share capital
Matthew Walls
CEO
5,254,832
30,428,453
30,428,453
14,235,473
1.89%
Paul Foulger
CFO
4,790,062
13,523,757
13,523,757
2,773,587
0.37%
Jordi Puig
COO
3,161,274
21,976,105
21,976,105
15,237,636
2.02%
William Rhodes
Non-Executive Chair
1,197,516
1,267,852
1,267,852
-
0.00%
Huon Gray
Non-Executive Director
837,423
1,267,852
1,267,852
1,905,405
0.25%
Felix Frueh
Non-Executive Director
837,423
845,235
845,235
600,000
0.08%
Sergio Olivero
Non-Executive Director
172,188
2,535,704
2,535,704
24,917,243
3.31%
Other Employees
13,605,716
12,002,334
14,078,585
N/A
N/A
Total:
29,856,434
83,847,292
85,923,543
58,395,757
7.75%

 

Directors and employees of the Group surrendered Options over an aggregate of 29,856,434 Ordinary Shares. The grant of 71,844,958 New Options exercisable at 1 pence to Matthew Walls, Paul Foulger, Jordi Puig, William Rhodes, Huon Gray, Sergio Olivero, and Felix Frueh are intended to replace their surrendered Options.

 

Following the grant of the New Options and the Options Surrender, there are Options over a total of 85,923,543 Ordinary Shares in the Company as at the date of this announcement, representing approximately 11.41% of the Company's existing issued share capital. 

 

For more information visit www.genincode.com

Enquiries:

 

GENinCode Plc
www.genincode.com or via Walbrook PR
Matthew Walls, CEO
Cavendish Capital Markets Limited
Tel: +44 (0) 20 7220 0500
Giles Balleny / Trisyia Jamaludin (Corporate Finance)
Nigel Birks (Specialist Sales)
Harriet Ward (Corporate Broking)
Walbrook PR Limited
Tel: 020 7933 8780 or
Anna Dunphy
genincode@walbrookpr.com

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict cardiovascular disease.

 

 

The notification set out below is provided in accordance with the requirements of MAR.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
1. Matthew Walls
2. Paul Foulger
3. Jordi Puig
4. William Rhodes
5. Huon Gray
6. Felix Frueh
7. Sergio Olivero
2
Reason for notification
a.
Position/Status
1. Chief Executive Officer
2. Chief Financial Officer
3. Chief Operating Officer
4. Non-Executive Chair
5. Non-Executive Director
6. Non-Executive Director
7. Non-Executive Director
b.
Initial notification/
Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
GENinCode Plc
b.
LEI
213800UX6TE7K65O2892
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument

Identification Code
Options over Ordinary Shares of 1p each
N/A
b.
Nature of the transaction
Grant of options under the 2021 Share Option Plan with time vesting conditions attached
c.
Price(s) and volume(s)
Exercise Price(s)
Volume(s)
1.
1 pence
30,428,453
2.
1 pence
13,523,757
3.
1 pence
21,976,105
4.
1 pence
1,267,852
5.
1 pence
1,267,852
6.
1 pence
845,235
7.
1 pence
2,535,704
d.
Aggregated information
- Aggregated Volume
- Price
See above
e.
Date of the transaction
6 May 2026
f.
Place of the transaction
Outside a trading venue


 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHUNVWRNSUVRAR